The sequencing results suggested that this patient had a homologous recombination-deficient (HRD) tumor, with the loss of ATM and MRE11A, which are key genes involved in the process of homologous recombination (HR) repair, suggesting that we could try targeted therapy with poly ADP ribose polymerase (PARP) inhibitors: this patient was relatively sensitive to niraparib (class C), olaparib (class C), rucaparib (class C), and talazoparib (class C). Here, ATM is linked to neoplasm.